Remove Biosimilars Remove Communication Remove Magazine
article thumbnail

Bayer’s Eylea market grip set to slip as Alvotech biosimilar closes in

Pharmaceutical Technology

Alvotech has moved one step closer to entering the Eylea (aflibercept 2 mg) biosimilar market, after a European Medicines Agency (EMA) panel recommended approval of its copycat biologic. Go deeper with GlobalData Reports LOA and PTSR Model - Aflibercept Biosimilar in Age Related Macular. CucuMberStudio via Shutterstock.

article thumbnail

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence. We may still continue to send you service-related and other non-promotional communications. Reports Prescriber Opinions on Biosimilars in Immunology Data Insights The gold standard of business intelligence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Pharmaceutical Technology

Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Reports Biosimilars in Immunology Data Insights The gold standard of business intelligence. Go deeper with GlobalData Reports Chemotherapy in Pharmaceuticals: Platinum-based cancer drug composi. Find out more Sign up for our daily news round-up!

article thumbnail

FDA approves KalVista’s Ekterly for hereditary angioedema

Pharmaceutical Technology

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

Packaging 122
article thumbnail

Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold

Pharmaceutical Technology

Kaftrio loses patient protection in 2037, at which point biosimilars are set to enter the market. Trikafta, known under the brand name Kaftrio in Europe, is the best-selling cystic fibrosis drug in the world, generating revenue of $11.02bn in 2024. Historically, this erodes the market dominance held by the branded drug.

article thumbnail

Big pharma braces for revenue headwinds as patent expiries loom

Pharmaceutical Technology

Biosimilars and generics flood the market upon patent loss, which exerts pricing pressure on the branded product. There has been a push by the Trump administration to increase biosimilar and generic drug use in the US. Biosimilars and generics can be as much as 80% cheaper than branded alternatives.

article thumbnail

DoH and Children’s National Hospital link for cell and gene therapy

Pharmaceutical Technology

We may still continue to send you service-related and other non-promotional communications. By Cytiva Thematic You have a right to withdraw your consent at any time, by clicking here. For more information relating to our privacy practices, we invite you to review our privacy policy. Sign up for our daily news round-up!